SEC Comment Letter for Pluri Inc. (PLUR) (CIK 0001158780) (PLUR) — May 14, 2020
Pluri Inc. (PLUR) (CIK 0001158780)
Date: May 14, 2020 · CIK: 0001158780 · Accession: 0000000000-20-004297
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-31392
Letter
United States securities and exchange commission logo May 14, 2020 Chen Franco-Yehuda Chief Financial Officer Pluristem Therapeutics Inc. Matam Advanced Technology Park Building No. 5 Haifa, Israel, 3508409 Re:Pluristem Therapeutics Inc. Preliminary Proxy Statement on Schedule 14A Filed April 30, 2020 File No. 001-31392 Dear Ms. Franco-Yehuda: We have reviewed your filing and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to these comments within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comments apply to your facts and circumstances, please tell us why in your response. After reviewing your response to these comments, we may have additional comments. Preliminary Proxy Statement on Schedule 14A Proposal No. 3 - Increase the Number of Authorized Shares of Common Stock, page 9 1.Please revise the proxy statement to indicate whether you currently have any plans, arrangements or understandings, written or oral, to issue any of the authorized but unissued shares that would become available as a result of the amendment to the Articles of Incorporation. 2.Please expand the disclosure regarding the potential sale of equity securities in order to utilize funds that may be loaned by the European Investment Bank. Please discuss whether you have cash on hand to satisfy your funding obligations under the Finance Contract or if you will need to raise capital through equity sales, and, if capital raises are necessary, at what times and amounts and through what types of offerings.
FirstName LastNameChen Franco-Yehuda Comapany NamePluristem Therapeutics Inc. May 14, 2020 Page 2 FirstName LastName Chen Franco-Yehuda Pluristem Therapeutics Inc. May 14, 2020 Page 2 We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at (202) 551-6761 or Joe McCann at (202) 551-6262 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Ron Ben-Bassat
Show Raw Text
United States securities and exchange commission logo
May 14, 2020
Chen Franco-Yehuda
Chief Financial Officer
Pluristem Therapeutics Inc.
Matam Advanced Technology Park
Building No. 5
Haifa, Israel, 3508409
Re:Pluristem Therapeutics Inc.
Preliminary Proxy Statement on Schedule 14A
Filed April 30, 2020
File No. 001-31392
Dear Ms. Franco-Yehuda:
We have reviewed your filing and have the following comments. In some of our
comments, we may ask you to provide us with information so we may better understand your
disclosure.
Please respond to these comments within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe our
comments apply to your facts and circumstances, please tell us why in your response.
After reviewing your response to these comments, we may have additional comments.
Preliminary Proxy Statement on Schedule 14A
Proposal No. 3 - Increase the Number of Authorized Shares of Common Stock, page 9
1.Please revise the proxy statement to indicate whether you currently have any
plans, arrangements or understandings, written or oral, to issue any of the authorized
but unissued shares that would become available as a result of the amendment to the
Articles of Incorporation.
2.Please expand the disclosure regarding the potential sale of equity securities in order to
utilize funds that may be loaned by the European Investment Bank. Please discuss
whether you have cash on hand to satisfy your funding obligations under the Finance
Contract or if you will need to raise capital through equity sales, and, if capital raises are
necessary, at what times and amounts and through what types of offerings.
FirstName LastNameChen Franco-Yehuda
Comapany NamePluristem Therapeutics Inc.
May 14, 2020 Page 2
FirstName LastName
Chen Franco-Yehuda
Pluristem Therapeutics Inc.
May 14, 2020
Page 2
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Please contact Chris Edwards at (202) 551-6761 or Joe McCann at (202) 551-6262 with
any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Ron Ben-Bassat